At present, knowledge on the biological complexity of colorectal tumors suggests that RAS status alone is not sufficient to select patients more likely to respond to anti-EGFR therapy and that probably despite RAS WT status, the presence of other mutations or losses of genes (such as BRAF, PTEN, EGFR) can affect the lack of response to treatment. Here, EGFR is linked to colorectal neoplasm.